```html

Nasal Mucosal Melanoma – A Patient‑Friendly Medical Guide

Overview

Nasal mucosal melanoma (NMM) is a rare, aggressive cancer that originates from melanocytes (pigment‑producing cells) located in the lining (mucosa) of the nasal cavity and paranasal sinuses. Unlike the more common cutaneous (skin) melanoma, NMM does not develop from sun‑exposed skin and therefore has different risk factors, behavior, and treatment considerations.

• Who it affects: Adults, most commonly between ages 50–70. Slight male predominance (≈55 % men).
• Prevalence: Represents <1 % of all melanomas and <0.5 % of all head‑and‑neck cancers. In the United States, an estimated 400–500 new cases are diagnosed each year (American Cancer Society).
• Geography: Incidence is fairly uniform worldwide, but slightly higher rates have been reported in East Asian populations.

Symptoms

Because the nasal cavity is a concealed space, early disease often mimics benign sinus problems. Any persistent or worsening symptom should be evaluated by an ENT specialist.

Local nasal symptoms

• Nasal obstruction or congestion – feeling “blocked” on one side.
• Recurrent nosebleeds (epistaxis) – may be bright red and occur without trauma.
• Unexplained nasal discharge – watery, mucoid, or occasionally blood‑tinged.
• Facial pain or pressure – especially over the cheeks, forehead, or around the eyes.
• Decreased sense of smell (anosmia) or altered smell (parosmia).

Symptoms from sinus involvement

• Headache worsening with bending over.
• Swelling or tenderness over the cheekbones or the bridge of the nose.
• Dental pain or loosening of upper teeth when the tumor involves the maxillary sinus.

Symptoms indicating spread (metastasis)

• Persistent cough, chest pain, or shortness of breath – possible lung involvement.
• Unexplained weight loss, fatigue, or night sweats.
• Neurological signs – double vision, facial weakness, or numbness when the tumor invades the orbit or brain.

Causes and Risk Factors

The exact cause of mucosal melanoma is not fully understood, but several factors are thought to increase risk.

Genetic and molecular contributors

• Mutations in KIT, NRAS, and BRAF genes – found in up to 40 % of NMM cases (NIH, 2020).
• Chromosomal alterations – such as loss of chromosome 9p21 (CDKN2A) which regulates cell growth.

Established risk factors

• Age – incidence rises sharply after age 50.
• Sex – modest male predominance.
• Occupational exposure – long‑term exposure to wood dust, formaldehyde, nickel, or certain rubber chemicals has been linked to sinonasal cancers, including melanoma (CDC).
• Chronic inflammation – longstanding sinusitis or nasal polyps may create a microenvironment that fosters malignant transformation.
• Immunosuppression – organ‑transplant recipients or patients with HIV have higher rates of mucosal melanoma.

What does NOT cause NMM

• UV radiation – unlike cutaneous melanoma, sunlight is not a major factor.
• Family history of skin melanoma – only a small minority of mucosal melanoma patients have a hereditary predisposition.

Diagnosis

Because early symptoms overlap with benign sinus disease, a systematic work‑up is essential.

Clinical evaluation

1. History and physical exam – focused on nasal symptoms, duration, and any neurologic changes.
2. Nasal endoscopy – a flexible or rigid scope visualizes the tumor; allows biopsy.

Imaging studies

• CT scan (computed tomography) – delineates bone erosion, sinus extension, and helps surgical planning.
• MRI (magnetic resonance imaging) – superior for soft‑tissue detail, orbital or intracranial invasion.
• PET‑CT (positron emission tomography) – assesses metabolic activity and detects distant metastases.

Pathology & molecular testing

• Biopsy – histologic examination shows atypical melanocytes with pigmented cytoplasm. Immunohistochemical stains (S100, HMB‑45, Melan‑A) confirm melanocytic origin.
• Molecular profiling – tests for KIT, BRAF, NRAS mutations guide targeted therapy.

Staging

Staging follows the AJCC (American Joint Committee on Cancer) 8th edition system for mucosal melanoma of the head & neck, ranging from Stage I (localized) to Stage IV (distant metastasis). Accurate staging dictates treatment intensity.

Treatment Options

Management requires a multidisciplinary team: otolaryngology‑head & neck surgery, medical oncology, radiation oncology, pathology, and supportive‑care services.

Surgery

• Endoscopic sinus surgery – minimally invasive, used for small, localized tumors.
• Open approaches (e.g., lateral rhinotomy, craniofacial resection) – for extensive disease involving bone or orbit.
• Goal: achieve negative margins (R0 resection) while preserving function.

Radiation therapy

• Intensity‑modulated radiation therapy (IMRT) – delivers high doses precisely to the tumor, sparing nearby structures.
• Proton beam therapy – useful for skull‑base disease where conventional photons risk excess toxicity.
• Adjuvant radiation is recommended in most cases because surgical margins are often microscopically positive.

Systemic therapy

• Immunotherapy – checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) have shown response rates of 20–30 % in mucosal melanoma, albeit lower than cutaneous disease (Cleveland Clinic).
• Targeted therapy – for tumors with KIT mutations, agents such as imatinib or nilotinib may be effective.
• Chemotherapy – historically dacarbazine or temozolomide; now rarely first‑line but may be used when immunotherapy is contraindicated.

Clinical trials

Enrollment in studies investigating novel agents (e.g., combination PD‑1 + CTLA‑4 blockade, TIGIT inhibitors) is encouraged, especially for recurrent or metastatic disease.

Supportive & lifestyle measures

• Smoking cessation – improves wound healing and overall outcomes.
• Nutrition optimization – high‑protein diet to support recovery.
• Physical therapy – maintains facial muscle function after extensive surgery.

Living with Nasal Mucosal Melanoma

Life after diagnosis involves regular surveillance, symptom management, and psychosocial support.

Follow‑up schedule

• First year: ENT exam + nasal endoscopy + imaging (CT/MRI) every 3–4 months.
• Years 2–5: every 6 months.
• After 5 years: annually, or sooner if symptoms recur.

Managing common side effects

• Post‑operative crusting or dryness – saline nasal rinses 2–3 times daily; humidifier at night.
• Radiation‑induced rhinitis or sinusitis – nasal steroids (fluticasone spray) and decongestants as needed.
• Immunotherapy‑related adverse events – monitor for rash, diarrhea, thyroid changes; report promptly to oncologist.

Emotional & practical support

• Join support groups (e.g., Melanoma Research Foundation patient network).
• Consider counseling or therapy to address anxiety or depression.
• Workplace accommodations – discuss with employer for time off for appointments.

Rehabilitation

When surgery involves the palate or orbit, speech and swallowing therapy may be necessary. Early referral to a speech‑language pathologist improves outcomes.

Prevention

Because many risk factors are non‑modifiable, prevention focuses on early detection and reducing known environmental exposures.

• Occupational safety – use protective equipment (masks, ventilation) when working with wood dust, chemicals, or solvents.
• Control chronic sinus disease – treat persistent sinusitis, nasal polyps, and allergic rhinitis promptly.
• Avoid tobacco – smoking worsens mucosal inflammation and impairs healing.
• Regular ENT evaluation for individuals with longstanding nasal complaints, especially if they have occupational exposures.

Complications

If left untreated or if disease progresses, several serious complications can arise.

• Local invasion – erosion into the orbit causing vision loss, or into the skull base leading to cerebrospinal fluid leak and meningitis.
• Bleeding – large tumors can cause recurrent or massive epistaxis requiring transfusion.
• Permanent nasal obstruction or facial deformity after extensive surgery.
• Distant metastasis – lungs, liver, brain; associated with a 5‑year survival of <15‑30 % for Stage IV disease (Mayo Clinic).
• Treatment‑related toxicity – radiation necrosis, immunotherapy‑induced colitis, endocrine dysfunction.

When to Seek Emergency Care

Timely medical attention can prevent life‑threatening complications and improve overall prognosis.

---

Sources: American Cancer Society, 2023; Mayo Clinic. Nasal Cavity and Paranasal Sinus Cancer. 2022; CDC – Occupational Risk Factors for Sinonasal Cancer. 2021; NIH – Molecular Landscape of Mucosal Melanoma. 2020; Cleveland Clinic. Melanoma Treatment Guidelines. 2023; WHO Cancer Fact Sheets, 2022.

```